Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Thoracic 1

Conditions

Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Brain Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 49Carboplatin 35Pemetrexed 29Cisplatin 26Docetaxel 23Nivolumab 21Paclitaxel 20Gemcitabine 15Magnetic Resonance Spectroscopy 14Specimen Handling 12Radiotherapy 12Cyclophosphamide 12Radiosurgery 11130-nm albumin-bound paclitaxel 11Erlotinib Hydrochloride 10Bevacizumab 10osimertinib 9Cetuximab 8Temozolomide 7Taxes 7Ipilimumab 7Biopsy 7fludarabine 6Ramucirumab 6Radiation 6veliparib 5tislelizumab 5durvalumab 5cemiplimab 5atezolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Mass Spectrometry × Thoracic × Clear all
NCT00738335 2012-10-04

Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases

University of California, San Francisco

Phase 1 Withdrawn
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡